The Effects of Bindarit in Diabetic Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01109212|
Recruitment Status : Completed
First Posted : April 23, 2010
Last Update Posted : March 30, 2016
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Nephropathy||Drug: Bindarit Drug: Placebo||Phase 2|
This is a pilot phase II, double-blind, multicentre, randomized, placebo-controlled, parallel groups study in patients with DN undergoing irbesartan therapy.
According to screening urinary albumin excretion, at baseline and before randomization, all patients will be categorized into 2 strata:
Stratum 1: microalbuminuria (20 to 200 μg/min, in at least 2 of 3 consecutive overnight urine samples collected at the screening) Stratum 2: macroalbuminuria (>200 μg/min, in at least 2 of 3 consecutive overnight urine samples collected at the screening).
Within each stratum, patients will be randomly allocated on a 1:1 basis to the 2 treatment arms (after one month induction period):
- bindarit 600MG twice a day
- placebo All patients will be treated with irbesartan 300 mg/day as background therapy. After 12 months of treatment albuminuria will be evaluated as primary endopoint.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||The Effects of the Association Bindarit + Irbesartan Versus Irbesartan Alone on Albuminuria on Patients With Diabetic Nephropathy. Placebo-controlled Study|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||November 2008|
|Actual Study Completion Date :||December 2008|
Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
Other Name: AF2838
Placebo Comparator: Placebo
patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
- Urinary Albumin Excretion (µg/min) levels in the overnight urine specimen. [ Time Frame: 12 weeks ]Relative change (per cent change) in Urinary Albumin Excretion (UAE) from the baseline
- Urinary Monocyte Chemoattractant protein (MCP-1/CCL2)(pg/ml) levels in the overnight urine specimen. [ Time Frame: 12 weeks ]Relative change (per cent change) in Urinary MCP-1 levels from the baseline.
- Serum lipids [ Time Frame: 12 weeks ]Relative change (per cent change) in total cholesterol, cholesterol HDL, triglycerides, apolipoprotein-A, apolipoprotein-B from the baseline.
- Safety and tolerability of bindarit in association of irbesartan. [ Time Frame: 12 weeks ]Changes in anthropometrics, laboratory parameters and vital signs from the baseline. Number of adverse events.
- Albuminuria remission rates [ Time Frame: 12 weeks ]Rate of remission from macro to microalbuminuria and from micro to normoalbuminuria.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01109212
|The Mario Negri Institute for Pharmacological Research- Clinical Research Center for Rare Diseases|
|Ranica, Bergamo, Italy, 24020|
|Azienda Ospedaliera di Treviglio-Caravaggio - Unità Operativa Malattie Metaboliche e Diabetologia|
|Treviglio, Bergamo, Italy, 24047|
|Azienda Ospedaliera OO.RR. Bergamo - Unità Operativa Diabetologia|
|Bergamo, Italy, 24128|
|IRCCS Fondazione Centro S. Raffaele del Monte Tabor- Unità Operativa Medicina Generale|
|Milano, Italy, 20132|
|Ist. Patologia Medica e metodologia Clinica - Università di Sassari|
|Sassari, Italy, 7100|
|University Medical Center Dpt Endocrinology Diabetes and Metabolic Diseases- Diabetology Unit|
|Ljubljana, Slovenia, 1000|
|Principal Investigator:||Giuseppe Remuzzi, PhD||Mario Negri Institute for Pharmacological Research|